RU2006134000A - Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с - Google Patents
Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с Download PDFInfo
- Publication number
- RU2006134000A RU2006134000A RU2006134000/04A RU2006134000A RU2006134000A RU 2006134000 A RU2006134000 A RU 2006134000A RU 2006134000/04 A RU2006134000/04 A RU 2006134000/04A RU 2006134000 A RU2006134000 A RU 2006134000A RU 2006134000 A RU2006134000 A RU 2006134000A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- group
- alkyl
- heterocyclyl
- pharmaceutical composition
- Prior art date
Links
- 0 *CC1NCC1 Chemical compound *CC1NCC1 0.000 description 42
- JHCRGWVAEYIVAN-UHFFFAOYSA-N CC(C)(C)N(CCN1C[IH]C)S1(=O)=O Chemical compound CC(C)(C)N(CCN1C[IH]C)S1(=O)=O JHCRGWVAEYIVAN-UHFFFAOYSA-N 0.000 description 1
- PBZHTQZXXTXWTK-QXXIUIOUSA-N CC(C)(CC1C2)[C@@H]1[C@@H](C(C)=O)N2C(C)=O Chemical compound CC(C)(CC1C2)[C@@H]1[C@@H](C(C)=O)N2C(C)=O PBZHTQZXXTXWTK-QXXIUIOUSA-N 0.000 description 1
- IDKAJTIEEAKXAB-VIFPVBQESA-N CC(C)(C[C@H]1C(C)=O)CN1C(C)=O Chemical compound CC(C)(C[C@H]1C(C)=O)CN1C(C)=O IDKAJTIEEAKXAB-VIFPVBQESA-N 0.000 description 1
- NLOOSIQADIMKFF-AEJSXWLSSA-N CC(C)(O[C@H]1C2)O[C@@H]1[C@@H](C(C)=O)N2C(C)=O Chemical compound CC(C)(O[C@H]1C2)O[C@@H]1[C@@H](C(C)=O)N2C(C)=O NLOOSIQADIMKFF-AEJSXWLSSA-N 0.000 description 1
- BYKYPYPHULOVEW-UHFFFAOYSA-N CC(C)C(CC1)CCC1(F)F Chemical compound CC(C)C(CC1)CCC1(F)F BYKYPYPHULOVEW-UHFFFAOYSA-N 0.000 description 1
- XPCKQTDUEAQGTK-UWYWSCPESA-N CC(C)C(CC1)[C@@H](C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)N1C([C@H](C(C)(C)C)NC(NC(CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O Chemical compound CC(C)C(CC1)[C@@H](C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)N1C([C@H](C(C)(C)C)NC(NC(CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O XPCKQTDUEAQGTK-UWYWSCPESA-N 0.000 description 1
- FKHKVNXFZNSTGO-YYDDNLMPSA-N CC(C)C(CC1)[C@@H](C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)N1C([C@H](C1CCCCC1)NC(N[C@H](CN(CCCN1C)S1(=O)=O)C(C)(C)C)=O)=O Chemical compound CC(C)C(CC1)[C@@H](C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)N1C([C@H](C1CCCCC1)NC(N[C@H](CN(CCCN1C)S1(=O)=O)C(C)(C)C)=O)=O FKHKVNXFZNSTGO-YYDDNLMPSA-N 0.000 description 1
- UPJQYODQOCCRRR-HCIQBXGHSA-N CC(C)C(C[C@H]1C(NC(CC2CC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O Chemical compound CC(C)C(C[C@H]1C(NC(CC2CC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O UPJQYODQOCCRRR-HCIQBXGHSA-N 0.000 description 1
- RZWOTQFLJRNXJA-FBGLDOHJSA-N CC(C)C(C[C@H]1C(NC(CC2CCC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O Chemical compound CC(C)C(C[C@H]1C(NC(CC2CCC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O RZWOTQFLJRNXJA-FBGLDOHJSA-N 0.000 description 1
- DZICCLVVNVURFW-UHFFFAOYSA-N CC(C)C1(C)CCOCC1 Chemical compound CC(C)C1(C)CCOCC1 DZICCLVVNVURFW-UHFFFAOYSA-N 0.000 description 1
- IOOXDDQLNSTLNL-UHFFFAOYSA-N CC(C)CN(CCCC1)C1=O Chemical compound CC(C)CN(CCCC1)C1=O IOOXDDQLNSTLNL-UHFFFAOYSA-N 0.000 description 1
- JNVUDATVGQZFOI-UHFFFAOYSA-N CC(C)CN(CCCN1)C1=O Chemical compound CC(C)CN(CCCN1)C1=O JNVUDATVGQZFOI-UHFFFAOYSA-N 0.000 description 1
- MOQYJGPXVIAPOT-UHFFFAOYSA-N CC(C)CN(Cc1ccccc11)S1(=O)=O Chemical compound CC(C)CN(Cc1ccccc11)S1(=O)=O MOQYJGPXVIAPOT-UHFFFAOYSA-N 0.000 description 1
- JKHCHASMRXRYGE-UHFFFAOYSA-N CC(C)CN1SCCCC1=O Chemical compound CC(C)CN1SCCCC1=O JKHCHASMRXRYGE-UHFFFAOYSA-N 0.000 description 1
- XEVXLJNFZXAVSC-IPBGHOEGSA-N CC(C)[C@@H](CN(CCC1)S1(=O)=O)NC(N[C@@H](C(C)(C)C)C(N(CC(C1)C(C)C)[C@@H]1C(NC(CC1CC1)C(C(NC)=O)=O)=O)=O)=O Chemical compound CC(C)[C@@H](CN(CCC1)S1(=O)=O)NC(N[C@@H](C(C)(C)C)C(N(CC(C1)C(C)C)[C@@H]1C(NC(CC1CC1)C(C(NC)=O)=O)=O)=O)=O XEVXLJNFZXAVSC-IPBGHOEGSA-N 0.000 description 1
- VIEKEHJFNWZURG-VEBXRMAPSA-N CC(C)[C@H](C[C@H]1C(NC(CC2CCC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(CCN1)S1(=O)=O)C(C)(C)C)=O)=O Chemical compound CC(C)[C@H](C[C@H]1C(NC(CC2CCC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(CCN1)S1(=O)=O)C(C)(C)C)=O)=O VIEKEHJFNWZURG-VEBXRMAPSA-N 0.000 description 1
- YDVYHEXBRNKDJG-HSOSERFQSA-N CC(C[C@H]1C(C)=O)CN1C(C)=O Chemical compound CC(C[C@H]1C(C)=O)CN1C(C)=O YDVYHEXBRNKDJG-HSOSERFQSA-N 0.000 description 1
- HPRITURHSXTUDO-JGVFFNPUSA-N CC([C@H]([C@H](CC1)C(Cl)Cl)N1C(C)=O)=O Chemical compound CC([C@H]([C@H](CC1)C(Cl)Cl)N1C(C)=O)=O HPRITURHSXTUDO-JGVFFNPUSA-N 0.000 description 1
- KFGFSYAJELATDC-BIIVOSGPSA-N CC([C@H]([C@H]([C@@H]1C2)C1(Cl)Cl)N2C(C)=O)=O Chemical compound CC([C@H]([C@H]([C@@H]1C2)C1(Cl)Cl)N2C(C)=O)=O KFGFSYAJELATDC-BIIVOSGPSA-N 0.000 description 1
- ZOLOOMHRCHIDJK-BIIVOSGPSA-N CC([C@H]([C@H]([C@@H]1C2)C1(F)F)N2C(C)=O)=O Chemical compound CC([C@H]([C@H]([C@@H]1C2)C1(F)F)N2C(C)=O)=O ZOLOOMHRCHIDJK-BIIVOSGPSA-N 0.000 description 1
- MHHRVAYBKLATSY-HCIQBXGHSA-N CCCCC(C(C(N)=O)=O)NC([C@H](CC(C1)C(C)C)N1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O)=O Chemical compound CCCCC(C(C(N)=O)=O)NC([C@H](CC(C1)C(C)C)N1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O)=O MHHRVAYBKLATSY-HCIQBXGHSA-N 0.000 description 1
- UXSITJBDGCVNCB-VJBGASIXSA-N CCCCC(C(C(NCC)=O)=O)NC([C@H](C[C@H](C1)C(C)C)N1C([C@H](C1CCCCC1)NC(NC(CC(C)(C)C)CN(CCC1)S1(=O)=O)=O)=O)=O Chemical compound CCCCC(C(C(NCC)=O)=O)NC([C@H](C[C@H](C1)C(C)C)N1C([C@H](C1CCCCC1)NC(NC(CC(C)(C)C)CN(CCC1)S1(=O)=O)=O)=O)=O UXSITJBDGCVNCB-VJBGASIXSA-N 0.000 description 1
- KDTYAJFCKAXXNQ-DUECVZMVSA-N CCCCC(C(C(NCC=C)=O)=O)NC([C@H](C(C1C2)C1(Cl)Cl)N2C([C@H](C(C)(C)C)NC(N[C@H](CN(C(c1c2cccc1)=O)C2=O)C(C)(C)C)=O)=O)=O Chemical compound CCCCC(C(C(NCC=C)=O)=O)NC([C@H](C(C1C2)C1(Cl)Cl)N2C([C@H](C(C)(C)C)NC(N[C@H](CN(C(c1c2cccc1)=O)C2=O)C(C)(C)C)=O)=O)=O KDTYAJFCKAXXNQ-DUECVZMVSA-N 0.000 description 1
- LKCCLYGBSKWNTR-OKLZREHDSA-N CCCCC(C(C(NCC=C)=O)=O)NC([C@H](C(CC1)C(C)C)N1C([C@H](C1CCCCC1)NC(NC(CN(C(CCC1(C)C)=O)C1=O)C(C)(C)C)=O)=O)=O Chemical compound CCCCC(C(C(NCC=C)=O)=O)NC([C@H](C(CC1)C(C)C)N1C([C@H](C1CCCCC1)NC(NC(CN(C(CCC1(C)C)=O)C1=O)C(C)(C)C)=O)=O)=O LKCCLYGBSKWNTR-OKLZREHDSA-N 0.000 description 1
- PJPZFHYMCATOJL-UHFFFAOYSA-N CCCN(C(CCN1C)=O)C1=O Chemical compound CCCN(C(CCN1C)=O)C1=O PJPZFHYMCATOJL-UHFFFAOYSA-N 0.000 description 1
- BELGHMWMXFCZTP-UHFFFAOYSA-N CCN(CCO1)C1=O Chemical compound CCN(CCO1)C1=O BELGHMWMXFCZTP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54850604P | 2004-02-27 | 2004-02-27 | |
| US60/548,506 | 2004-02-27 | ||
| PCT/US2005/005924 WO2005085242A1 (en) | 2004-02-27 | 2005-02-24 | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006134000A true RU2006134000A (ru) | 2008-04-10 |
Family
ID=34919371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134000/04A RU2006134000A (ru) | 2004-02-27 | 2005-02-24 | Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7173057B2 (enExample) |
| EP (1) | EP1730142B1 (enExample) |
| JP (1) | JP4874227B2 (enExample) |
| KR (1) | KR20070026394A (enExample) |
| CN (1) | CN1946718A (enExample) |
| AR (1) | AR048023A1 (enExample) |
| AT (1) | ATE514691T1 (enExample) |
| AU (1) | AU2005219824B2 (enExample) |
| BR (1) | BRPI0508217A (enExample) |
| CA (1) | CA2557304C (enExample) |
| EC (1) | ECSP066792A (enExample) |
| IL (1) | IL177628A0 (enExample) |
| NO (1) | NO20064355L (enExample) |
| PE (1) | PE20050999A1 (enExample) |
| RU (1) | RU2006134000A (enExample) |
| TW (1) | TW200529822A (enExample) |
| WO (1) | WO2005085242A1 (enExample) |
| ZA (1) | ZA200607048B (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1133649C (zh) | 1996-10-18 | 2004-01-07 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂 |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US8696298B2 (en) * | 2003-11-10 | 2014-04-15 | Brooks Automation, Inc. | Semiconductor manufacturing process modules |
| US10086511B2 (en) | 2003-11-10 | 2018-10-02 | Brooks Automation, Inc. | Semiconductor manufacturing systems |
| US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| US7192957B2 (en) * | 2004-02-27 | 2007-03-20 | Schering Corporation | Compounds as inhibitors of hepatitis C virus NS3 serine protease |
| US8119602B2 (en) | 2005-06-02 | 2012-02-21 | Schering Corporation | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
| WO2006130687A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
| EP1898941A2 (en) * | 2005-06-02 | 2008-03-19 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| ES2572980T3 (es) * | 2005-06-02 | 2016-06-03 | Merck Sharp & Dohme Corp. | Combinación de inhibidores de la proteasa del VHC con un tensioactivo |
| WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| GEP20105124B (en) | 2005-07-25 | 2010-11-25 | Array Biopharma Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| BRPI0617274A2 (pt) | 2005-10-11 | 2011-07-19 | Intermune Inc | compostos e métodos para a inibição de replicação viral de hepatite c |
| KR20140098867A (ko) | 2005-11-11 | 2014-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | Ｃ형 간염 바이러스 변이체 |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| KR101059593B1 (ko) | 2006-04-11 | 2011-08-25 | 노파르티스 아게 | Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도 |
| CN101421292A (zh) * | 2006-04-11 | 2009-04-29 | 诺瓦提斯公司 | Hcv抑制剂 |
| US20080045530A1 (en) * | 2006-04-11 | 2008-02-21 | Trixi Brandl | Organic Compounds and Their Uses |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| CN101506167A (zh) | 2006-08-17 | 2009-08-12 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| CA2673111A1 (en) | 2006-12-07 | 2008-06-19 | Schering Corporation | Ph sensitive matrix formulation |
| US20080219810A1 (en) * | 2007-03-05 | 2008-09-11 | Van Der Meulen Peter | Semiconductor manufacturing process modules |
| US20100104534A1 (en) * | 2007-03-23 | 2010-04-29 | Srikanth Venkatraman | Hydrazido-peptides as inhibitors of hcv ns3-protease |
| WO2009008913A2 (en) * | 2007-03-23 | 2009-01-15 | Schering Corporation | P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
| WO2008137779A2 (en) * | 2007-05-03 | 2008-11-13 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| MX2009012093A (es) * | 2007-05-10 | 2010-01-25 | Intermune Inc | Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c. |
| US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| JP5095824B2 (ja) | 2007-10-10 | 2012-12-12 | ノバルティス アーゲー | スピロピロリジン類およびｈｃｖおよびｈｉｖ感染に対するその使用 |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| BRPI0821342A2 (pt) | 2007-12-19 | 2019-09-24 | Boehringer Ingelheim Int | inibidores da polimerase viral |
| TW200936131A (en) | 2008-02-04 | 2009-09-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| CN102046622A (zh) * | 2008-04-15 | 2011-05-04 | 因特蒙公司 | 丙型肝炎病毒复制的新颖大环抑制剂 |
| CN102271699A (zh) | 2009-01-07 | 2011-12-07 | 西尼克斯公司 | 用于治疗hcv和hiv感染的环孢菌素衍生物 |
| US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2403860B1 (en) | 2009-03-04 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole as hcv polymerase inhibitors |
| WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8980920B2 (en) | 2009-05-29 | 2015-03-17 | Merck Sharp & Dohme Corp. | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C |
| CA2769652A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| AR079528A1 (es) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| US8609635B2 (en) | 2010-03-09 | 2013-12-17 | Merck Sharp & Dohme Corp. | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| CA2812779A1 (en) | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| JP5565320B2 (ja) * | 2011-01-06 | 2014-08-06 | 富士通株式会社 | 情報処理装置及び情報処理プログラム |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途 |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EA201391519A1 (ru) | 2011-04-13 | 2014-03-31 | Мерк Шарп И Доум Корп. | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний |
| CN103687489A (zh) | 2011-05-18 | 2014-03-26 | 埃南塔制药公司 | 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法 |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| CN104292130B (zh) * | 2014-10-13 | 2016-04-27 | 苏州永健生物医药有限公司 | 一种波普瑞韦中间体2-羟基-3-氨基-4-环丁基丁酰胺盐酸盐的合成方法 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN117836272B (zh) * | 2021-08-02 | 2025-02-28 | 北京华益健康药物研究中心 | 用于治疗或预防冠状病毒感染的3cl蛋白酶小分子抑制剂及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4462398A (en) * | 1982-12-03 | 1984-07-31 | Kircaldie, Randal and McNab, Trustee | Respirating gas supply method and apparatus therefor |
| SI1385870T1 (sl) | 2000-07-21 | 2010-08-31 | Schering Corp | Peptidi kot NS3-serin proteazni inhibitorji virusa hepatitisa C |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| NZ531681A (en) * | 2001-10-24 | 2007-05-31 | Vertex Pharma | Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system |
| JP4301953B2 (ja) * | 2002-01-23 | 2009-07-22 | シェーリング コーポレイション | Ｃ型肝炎ウイルス感染の処置における使用のためのｎｓ３−セリンプロテアーゼ阻害剤としてのプロリン化合物 |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| JP2005173784A (ja) * | 2003-12-09 | 2005-06-30 | Nec Corp | 映像情報配信システム及び方法と装置並びにプログラム |
| US7245891B2 (en) * | 2003-10-21 | 2007-07-17 | Kyocera Wireless Corp. | Wireless mobile communication device having a speaker vibration alert and method of using same |
| US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| US7342041B2 (en) * | 2004-02-27 | 2008-03-11 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease |
-
2005
- 2005-02-24 RU RU2006134000/04A patent/RU2006134000A/ru not_active Application Discontinuation
- 2005-02-24 AU AU2005219824A patent/AU2005219824B2/en not_active Ceased
- 2005-02-24 BR BRPI0508217-0A patent/BRPI0508217A/pt not_active IP Right Cessation
- 2005-02-24 EP EP05723688A patent/EP1730142B1/en not_active Expired - Lifetime
- 2005-02-24 AT AT05723688T patent/ATE514691T1/de not_active IP Right Cessation
- 2005-02-24 WO PCT/US2005/005924 patent/WO2005085242A1/en not_active Ceased
- 2005-02-24 KR KR1020067017349A patent/KR20070026394A/ko not_active Ceased
- 2005-02-24 TW TW094105517A patent/TW200529822A/zh unknown
- 2005-02-24 CA CA2557304A patent/CA2557304C/en not_active Expired - Fee Related
- 2005-02-24 CN CNA2005800126969A patent/CN1946718A/zh active Pending
- 2005-02-24 US US11/065,647 patent/US7173057B2/en not_active Expired - Fee Related
- 2005-02-24 JP JP2007500975A patent/JP4874227B2/ja not_active Expired - Fee Related
- 2005-02-24 PE PE2005000218A patent/PE20050999A1/es not_active Application Discontinuation
- 2005-02-25 AR ARP050100717A patent/AR048023A1/es not_active Application Discontinuation
-
2006
- 2006-08-22 IL IL177628A patent/IL177628A0/en unknown
- 2006-08-23 ZA ZA200607048A patent/ZA200607048B/xx unknown
- 2006-08-25 EC EC2006006792A patent/ECSP066792A/es unknown
- 2006-09-26 NO NO20064355A patent/NO20064355L/no not_active Application Discontinuation
- 2006-11-20 US US11/602,174 patent/US7619094B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO20064355L (no) | 2006-11-24 |
| ATE514691T1 (de) | 2011-07-15 |
| AU2005219824B2 (en) | 2007-11-29 |
| US7619094B2 (en) | 2009-11-17 |
| PE20050999A1 (es) | 2005-12-01 |
| CA2557304A1 (en) | 2005-09-15 |
| ZA200607048B (en) | 2008-06-25 |
| EP1730142B1 (en) | 2011-06-29 |
| WO2005085242A1 (en) | 2005-09-15 |
| US20050222047A1 (en) | 2005-10-06 |
| EP1730142A1 (en) | 2006-12-13 |
| JP2007525518A (ja) | 2007-09-06 |
| AR048023A1 (es) | 2006-03-22 |
| JP4874227B2 (ja) | 2012-02-15 |
| US7173057B2 (en) | 2007-02-06 |
| TW200529822A (en) | 2005-09-16 |
| CN1946718A (zh) | 2007-04-11 |
| IL177628A0 (en) | 2006-12-31 |
| KR20070026394A (ko) | 2007-03-08 |
| AU2005219824A1 (en) | 2005-09-15 |
| CA2557304C (en) | 2013-08-06 |
| ECSP066792A (es) | 2006-11-16 |
| US20070093430A1 (en) | 2007-04-26 |
| BRPI0508217A (pt) | 2007-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006134000A (ru) | Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с | |
| RU2006134002A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2006134005A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2404189C9 (ru) | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита c | |
| RU2006124594A (ru) | Ингибиторы сериновой протеазы ns3/ns4а вируса гепатита с | |
| JP2007535496A5 (enExample) | ||
| JP2007525514A5 (enExample) | ||
| JP2007525518A5 (enExample) | ||
| JP2007525510A5 (enExample) | ||
| CA2410662A1 (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| JP2007525512A5 (enExample) | ||
| RU2003105217A (ru) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| JP2008511633A5 (enExample) | ||
| RU2003105221A (ru) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| JP2004513881A5 (enExample) | ||
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| RU2000102359A (ru) | Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты | |
| JP2004504404A5 (enExample) | ||
| RU2002129564A (ru) | Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с | |
| RU2002131163A (ru) | Макроциклические ингибиторы ns3-серинпротезы вируса гепатита с, содержащие алкил- и арилаланиновые p2 фрагменты | |
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| RU2003101319A (ru) | Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты | |
| CN111836814A (zh) | 稠环化合物、其制备方法及用途 | |
| RU2010133979A (ru) | Синтез лактонов резорциловой кислоты, используемых в качестве терапевтических агентов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20101101 |